Teva Announces Fda Approval Of Generic Tobi(r) In The United States

Soccer keeps reminding us how few opportunities there will be to gather the first team ahead of next summers World Cup. No opportunity can be wasted. Thats why the United States Soccer federation has announced its latest friendly, set for Nov. 19 in Vienna against Austria . These teams havent met since 1998. That match will follow a Nov. 15 contest against Scotland at Glasgows famed Hampden Park. Thats the last well see of the national team until the annual January camp which will look quite different this time around. U.S. Soccer isnt officially talking about the January camp yet, but officials will quietly allow that part of the camp will take place in Brazil. It will still be a camp for MLS types and for any Scandinavian league men on break. So that means 14-16 first-choice types wont be able to take advantage of a trip that is mostly about getting familiar with the terrain. Still, it should be a useful exercise for those involved, and for Klinsmann (pictured) and the U.S. coaching staff, of course.

United States Cellular Corporation : U.S. Cellular Unveils Shared Data Plans for Consumers and Business

Marketed by Novartis, TOBI(R) had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products, competition for our innovative products, especially COPAXONE(R) (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our specialty, including innovative, R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S.

The United States pre-World Cup schedule keeps filling up

14, 2013) – U.S. With these new plans, customers can build the plan that best meets the wireless needs of their families or employees without having to keep track of multiple plans or accounts. U.S. Customers can share a single bucket of data among their smartphones, basic phones, tablets, hotspots and wireless modems. U.S. “At U.S. Cellular, providing an exceptional wireless experience is our number one goal, and we strive to provide it through our high-quality network along with devices and plans that meet our customers’ needs,” said Joe Settimi, vice president of products, pricing and innovation for U.S. Cellular. They can then choose the amount of data that matches up with their usage on those devices from plans that start at 300 MB for $40 and go up to 75 GB for $560 per month. Business customers can select up to 25 devices to share up to 100 GB of data for $750 per month. Tethering is included on all plans. Smartphones have a monthly device connection charge of $40, basic phones are $30, hotspots and wireless modems are $20 and tablets can be added for $10 per month.